Androstenedione intranasal - Mattern

Drug Profile

Androstenedione intranasal - Mattern

Latest Information Update: 14 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mattern Pharmaceuticals
  • Class Hormones
  • Mechanism of Action Androgen receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Polycystic ovary syndrome; Traumatic stress disorders

Most Recent Events

  • 14 Jul 2016 Chemical structure information added
  • 07 Jul 2016 Preclinical trials in Polycystic ovary syndrome in Switzerland (Intranasal)
  • 07 Jul 2016 Preclinical trials in Stress disorders in Switzerland (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top